Expanding its offering of passive safety devices to protect both clinicians and patients from needlestick injuries (NSIs), B. Braun Medical Inc. (B. Braun) recently announced that the Food and Drug Administration (FDA) granted 510(k) clearance of the companys Introcan Safety® 3 Closed IV Catheter, the next generation of B. Brauns Introcan Safety® IV Catheter. B. Braun made the announcement during the Association for Vascular Access 2011 annual scientific meeting in San Jose, Calif. in early October.
"Recent research confirms passive safety engineered devices are most effective for needlestick injury prevention," says Tom Sutton, vice president of vascular ccess and IV systems for B. Braun Medical Inc. "The Introcan Safety® 3 is designed to provide clinicians with not only an effective passive needlestick safety device, but also an added layer of safety and control with a bidirectional blood control valve to aid in the prevention of blood exposure each time the device is accessed."
The Introcan Safety® 3 features all elements of B. Brauns existing and proven Introcan Safety® IV Catheter. From insertion to advancing the catheter to needle removal, the Introcan Safety® 3 is designed to help protect clinicians and patients from NSIs as the device cannot be bypassed or activated inadvertently.
B. Brauns Introcan Safety® 3 will provide protection through Passive Safety Needle Shield to aid in the prevention of NSIs; Multiple Access Blood Control Valve to aid in the prevention of blood exposure; and Integrated Stabilization Platform to improve catheter stability and minimize movement within the vessel
For more information, visit www.introcansafety.bbraunusa.com or call (800) 227-2862.